BOSTON, MA — December 8, 2025 — Praxis Precision Medicines presented compelling new clinical results at the American Epilepsy Society (AES) 2025 Annual Meeting, showcasing best-in-class therapeutic potential across rare pediatric and adult epilepsies. Data from the EMBOLD study of relutrigine and the RADIANT study of vormatrigine demonstrated robust seizure reduction, sustained functional improvements, and high responder rates, reinforcing Praxis’ position as a leader in genetically informed CNS drug development. The company also expanded its analytic framework for Developmental and Epileptic Encephalopathies (DEEs), further solidifying its strategic role in precision neurology.
Science Significance
The AES 2025 results highlight major progress in understanding and treating neuronal excitation-inhibition imbalance, the core biological mechanism driving severe genetic epilepsies. In the Phase 2 EMBOLD study, relutrigine achieved a 53% placebo-adjusted reduction in seizures and a 66% increase in motor seizure-free days, alongside significant improvements in alertness, communication, and behavior, with no drug-related serious adverse events. Meanwhile, vormatrigine demonstrated rapid, durable seizure reduction, achieving 100% median weekly seizure reduction in focal onset seizure patients continuing to 16 weeks. These findings validate Praxis’ precision NaV-channel modulation strategy, supporting the emergence of a new generation of molecularly targeted epilepsy therapies.
Regulatory Significance
Praxis’ results arrive at a critical moment as the company prepares for upcoming FDA interactions regarding a potential New Drug Application (NDA) for relutrigine. The therapy has already received multiple Orphan Drug Designations, Rare Pediatric Disease Designation, and Breakthrough Therapy Designation, reflecting strong regulatory recognition of its potential impact in rare epilepsies such as SCN2A-DEE and SCN8A-DEE. Vormatrigine continues advancing toward pivotal evidence in the POWER clinical program, with regulatory submissions anticipated as studies mature. These results strengthen Praxis’ pipeline positioning under global regulatory frameworks prioritizing innovation in underserved neurological disorders.
Business Significance
Advertisement
The AES dataset provides significant momentum for Praxis’ CNS-focused commercial strategy, reinforcing investor confidence in its diversified portfolio spanning ASO therapies, small molecules, and rare-disease neurology programs. Strong clinical performance across two mid-to-late-stage assets enhances the company’s competitive profile in a high-need therapeutic landscape. Completion of enrollment in the POWER1 pivotal study and continued progress toward POWER2 and POWER3 signal a maturing pipeline capable of generating near-term value while solidifying Praxis’ leadership in targeted epilepsy drug development
Patients’ Significance
For patients living with rare pediatric DEEs and drug-resistant adult epilepsies, the presented data offer meaningful clinical hope. Many EMBOLD participants had previously failed multiple therapies, yet relutrigine delivered rapid, sustained seizure reduction with a favorable safety profile. Vormatrigine’s ability to achieve seizure freedom in a subset of focal epilepsy patients—without titration—addresses a long unmet need for fast-acting, effective, and tolerable treatment options. These advances represent significant potential improvements in daily functioning, safety, and long-term quality of life for individuals who often face devastating, lifelong neurological challenges.
Policy Significance
The results highlight the importance of continued regulatory and policy support for rare-disease neuroscience, including accelerated pathways such as Breakthrough Therapy Designation and incentives for pediatric-focused drug development. As DEEs and genetic epilepsies place substantial burdens on families and healthcare systems, data like Praxis’ strengthen the argument for broader reimbursement frameworks, investment in precision-neurology research, and policies that facilitate clinical trial access for underserved populations. These findings align with global efforts to advance innovative CNS therapeutics through modernization of regulatory science and strengthened rare-disease policy infrastructure.
Praxis Precision Medicines’ AES 2025 presentation marks a pivotal advancement in precision epilepsy therapeutics, with relutrigine and vormatrigine demonstrating best-in-class potential across both rare and common epilepsies. As the company moves closer to regulatory milestones and pivotal trial completion, the new data reinforce its mission to transform treatment for patients with severe neurological disorders rooted in genetic dysfunction. Praxis’ scientifically driven approach continues to reshape the therapeutic landscape, signaling a future where targeted CNS treatments bring meaningful improvements to patients worldwide.
Source: Praxis press release
